CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
This study evaluates the combination of CBT-1® and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorubicin. Participants will receive CBT-1® on days 1-7 of each 21-day cycle, as well as doxorubicin on days 5 and 6.
Sarcoma
DRUG: CBT-1®
Maximum tolerated dose of CBT-1® when combined with doxorubicin, 3 years
Recommended phase 2 dose (RP2D) of CBT-1® when combined with doxorubicin, 3 years|Disease Control Rate (DCR) of CBT-1® when combined with doxorubicin, DCR = Overall Response Rate \[ORR = Complete Response + Partial Response\] + Stable Disease by RECIST 1.1, week 12|Overall Response Rate, 3 years
Correlation of DCR, ORR and PFS to disease subtype, 3 years|Correlation of P-gp expression at baseline to P-gp expression after treatment, 3 years|Correlation of tumor response to P-gp inhibition by CBT-1®, 3 years|Presence of CBT-1® in tumor tissue, 3 years
This study evaluates the combination of CBT-1® and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorubicin. Participants will receive CBT-1® on days 1-7 of each 21-day cycle, as well as doxorubicin on days 5 and 6.